ArticleNPJ vaccines2018
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.
Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01578317 (Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine), which is not on this map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine
Who cites it
56 citing papers in PubMed.
- The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination.Cell · 2021Trial
- Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.Nature communications · 2019Trial
- Article
- Pre-existing and cross-reactive immunity to avian influenza H5N1 in humans: Implications for pandemic risk and vaccine strategies.The Journal of infection · 2026Review
- Comparison of the adjuvant effect of AS01, AS03 and alum on the immune response to GMP-grade H5N1 antigen in guinea pigs.Scientific reports · 2026Article
- Review
- Evaluation of Cross-Immunogenicity of Ferret Antisera Following Immunization with H5N1 Vaccine Strains.Vaccines · 2026Article
- An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins.Nature communications · 2026Article
- Adjuvanted influenza vaccination increases pre-existing H5N1 cross-reactive antibodies.Nature communications · 2026Article
- Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.Nature immunology · 2025Article
- Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans.PLoS pathogens · 2025Article
- Review
- Distinct effects of adjuvants on B cell responses to protein or polysaccharide antigens contained in glycoconjugate vaccines.Frontiers in immunology · 2025Article
- System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.Nature immunology · 2025Article
- A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses and vaccine efficacy is determined by adjuvant and dosage.Emerging microbes & infections · 2024Article
- Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.Nature medicine · 2024Article
- Acute and persistent responses after H5N1 vaccination in humans.Cell reports · 2024Article
- Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.NPJ vaccines · 2024Article
- Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine AdjuvantsVaccines · 2024Article
- AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.Science immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immune responses to inactivated vaccines against avian influenza are poor due in part to lack of immune memory. Adjuvants significantly increased virus neutralizing titers. We performed comprehensive analyses of polyclonal antibody responses following FDA-approved adjuvanted H5N1-A/Indonesia vaccine, administered in presence or absence of AS03. Using Whole Genome Fragment Phage Display Libraries, we observed that AS03 induced antibody epitope diversity to viral hemagglutinin (HA) and neuraminidase compared with unadjuvanted vaccine. Furthermore, AS03 promoted significant antibody affinity maturation to properly folded H5-HA1 (but not to HA2) domain, which correlated with neutralization titers against both vaccine and heterologous H5N1 strains. However, no increase in heterosubtypic cross-neutralization of Group1-H1N1 seasonal strains was observed. AS03-H5N1 vaccine also induced higher neuraminidase inhibition antibody titers. This study provides insight into the differential impacts of AS03 adjuvant on H5N1 vaccine-induced antibody responses that may help optimize vaccine platforms for future vaccines with improved protection against seasonal and pandemic influenza strains.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.